Ascendis Pharma Announced Once-Weekly TransCon CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years
Ascendis Pharma A/S (Nasdaq: ASND) today announced positive topline results from the ACcomplisH Trial, its Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial evaluating the safety and efficacy of once-weekly TransCon CNP compared to placebo in children with achondroplasia aged 2 to 10 years old.
